VivoSim Labs (NASDAQ:VIVS – Get Free Report) and iSpecimen (NASDAQ:ISPC – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, dividends, risk, analyst recommendations, earnings and valuation.
Institutional & Insider Ownership
8.2% of VivoSim Labs shares are held by institutional investors. Comparatively, 13.6% of iSpecimen shares are held by institutional investors. 1.0% of VivoSim Labs shares are held by company insiders. Comparatively, 12.2% of iSpecimen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares VivoSim Labs and iSpecimen’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| VivoSim Labs | -11,016.07% | -612.23% | -177.02% |
| iSpecimen | -2,445.40% | -524.39% | -140.42% |
Volatility and Risk
Analyst Recommendations
This is a summary of current ratings and price targets for VivoSim Labs and iSpecimen, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| VivoSim Labs | 1 | 0 | 0 | 0 | 1.00 |
| iSpecimen | 1 | 0 | 0 | 0 | 1.00 |
Valuation & Earnings
This table compares VivoSim Labs and iSpecimen”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| VivoSim Labs | $130,000.00 | 28.59 | -$13.84 million | ($4.47) | -0.05 |
| iSpecimen | $466,302.00 | 6.81 | -$10.49 million | ($56.44) | -0.02 |
iSpecimen has higher revenue and earnings than VivoSim Labs. VivoSim Labs is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks.
Summary
iSpecimen beats VivoSim Labs on 9 of the 11 factors compared between the two stocks.
About VivoSim Labs
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
About iSpecimen
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Lexington, Massachusetts.
Receive News & Ratings for VivoSim Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VivoSim Labs and related companies with MarketBeat.com's FREE daily email newsletter.
